Search Results - "Nanavati, Nayan"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study by Goldstein, Steven R., Nanavati, Nayan

    “…Objective: Selective estrogen receptor modulators are novel compounds that bind to the estrogen receptor and have mixed agonistic and antagonistic activities…”
    Get full text
    Journal Article
  2. 2

    Initial 17β-Estradiol dose for treating vasomotor symptoms by Notelovitz, Morris, Lenihan, John P, McDermott, Michele, Kerber, Irwin J, Nanavati, Nayan, Arce, Joan-Carles

    Published in Obstetrics and gynecology (New York. 1953) (01-05-2000)
    “…Objective: To compare the efficacy of different doses of 17β-estradiol (E2) for relief of vasomotor symptoms in menopausal women. Methods: This was a…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Uterine Bleeding in Postmenopausal Women on Continuous Therapy With Estradiol and Norethindrone Acetate by ARCHER, DAVID F, DORIN, MAXINE H, HEINE, WAYNE, NANAVATI, NAYAN, ARCE, JOAN-CARLES

    Published in Obstetrics and gynecology (New York. 1953) (01-09-1999)
    “…OBJECTIVETo investigate the incidence of uterine bleeding during 12 months of treatment with 17β-estradiol (E2) 1 mg, unopposed or in combination with three…”
    Get full text
    Journal Article
  5. 5

    Norethindrone acetate and estradiol-induced endometrial hyperplasia by Kurman, Robert J, Félix, Juan Carlos, Archer, David F, Nanavati, Nayan, Arce, Joan-Carles, Moyer, Dean L

    Published in Obstetrics and gynecology (New York. 1953) (01-09-2000)
    “…Objective: To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate by Archer, David F, Dorin, Maxine H, Heine, Wayne, Nanavati, Nayan, Arce, Joan-Carles

    “…Objective: To investigate the incidence of uterine bleeding during 12 months of treatment with 17β-estradiol (E2) 1 mg, unopposed or in combination with three…”
    Get full text
    Journal Article
  9. 9

    Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women by Davidson, M H, Maki, K C, Marx, P, Maki, A C, Cyrowski, M S, Nanavati, N, Arce, J C

    Published in Archives of internal medicine (1960) (27-11-2000)
    “…To evaluate the influence of 2 continuous combined estrogen-progestin replacement products, compared with unopposed estrogen and placebo, on cardiovascular…”
    Get more information
    Journal Article